• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

咳嗽和咳痰评估问卷在 COPD 和慢性支气管炎加重期的反应性。

Responsiveness of the cough and sputum assessment questionnaire in exacerbations of COPD and chronic bronchitis.

机构信息

Boehringer Ingelheim GmbH, Binger Strasse 173, D-55216 Ingelheim, Germany.

出版信息

Respir Med. 2010 Apr;104(4):534-41. doi: 10.1016/j.rmed.2009.10.026. Epub 2009 Nov 14.

DOI:10.1016/j.rmed.2009.10.026
PMID:19917525
Abstract

BACKGROUND

To assess the responsiveness of the Cough and Sputum Assessment Questionnaire (CASA-Q) in COPD and chronic bronchitis patients recovering from an acute exacerbation. The 20-item questionnaire with a 7-day recall assesses the frequency and severity of cough and sputum and their impact on everyday life in clinical (trial) settings. The four domains (cough/sputum symptom and impact) use scales from 0 to 100, with lower scores indicating higher symptom/impact levels.

METHODS

Outpatients were enrolled within 48h of symptom onset of their exacerbation. Treatment was initiated at the discretion of the investigator, and patients observed for 6 weeks. During study visits, 59 eligible patients completed the CASA-Q at enrolment, week 1, 2 and 6. Responsiveness was assessed by calculating standardized effect sizes.

RESULTS

Of the 19 male and 40 female patients with a mean (standard deviation, SD) age of 61.1 (10.5) years, all were classified by their physician to have improved or recovered after six weeks. The mean (SD) CASA-Q sores for the cough symptom, cough impact, sputum symptom and sputum impact domains increased from 32.6 (21.0), 40.7 (22.4), 37.4 (20.1), 47.1 (24.2) at enrolment to 54.0 (19.8), 63.7 (21.3), 55.1 (19.0), 65.5 (20.5) at week 6, respectively. Standardized effect sizes for patients improved or recovered from their exacerbation at week 6 were above 1.0 for the cough domains and at least 0.77 for the sputum domains.

CONCLUSIONS

The CASA-Q was responsive to symptom changes in patients recovering from an exacerbation.

摘要

背景

评估咳嗽和痰评估问卷(CASA-Q)在 COPD 和慢性支气管炎患者急性加重后恢复的反应能力。该 20 项问卷有 7 天的回忆期,评估了咳嗽和痰的频率和严重程度及其对日常生活的影响在临床(试验)环境中。四个域(咳嗽/痰症状和影响)使用 0 到 100 的量表,分数越低表示症状/影响水平越高。

方法

在症状发作后 48 小时内招募门诊患者。治疗由研究者自行决定,并观察患者 6 周。在研究访问期间,59 名符合条件的患者在入组时、第 1 周、第 2 周和第 6 周完成了 CASA-Q。通过计算标准化效应大小来评估反应能力。

结果

19 名男性和 40 名女性患者的平均(标准差,SD)年龄为 61.1(10.5)岁,所有患者在六周后都被医生分类为改善或康复。咳嗽症状、咳嗽影响、痰症状和痰影响域的 CASA-Q 评分从入组时的 32.6(21.0)、40.7(22.4)、37.4(20.1)、47.1(24.2)增加到第 6 周的 54.0(19.8)、63.7(21.3)、55.1(19.0)、65.5(20.5),分别。第 6 周从急性加重中恢复的患者的标准化效应大小在咳嗽域中大于 1.0,在痰域中至少为 0.77。

结论

CASA-Q 对患者从急性加重中恢复时的症状变化敏感。

相似文献

1
Responsiveness of the cough and sputum assessment questionnaire in exacerbations of COPD and chronic bronchitis.咳嗽和咳痰评估问卷在 COPD 和慢性支气管炎加重期的反应性。
Respir Med. 2010 Apr;104(4):534-41. doi: 10.1016/j.rmed.2009.10.026. Epub 2009 Nov 14.
2
Development and validation of a cough and sputum assessment questionnaire.咳嗽与痰液评估问卷的编制与验证
Respir Med. 2008 Nov;102(11):1545-55. doi: 10.1016/j.rmed.2008.06.009. Epub 2008 Jul 27.
3
Effect of ELOM-080 on exacerbations and symptoms in COPD patients with a chronic bronchitis phenotype - a post-hoc analysis of a randomized, double-blind, placebo-controlled clinical trial.ELOM-080对慢性支气管炎表型慢性阻塞性肺疾病患者急性加重和症状的影响——一项随机、双盲、安慰剂对照临床试验的事后分析
Int J Chron Obstruct Pulmon Dis. 2016 Nov 23;11:2877-2884. doi: 10.2147/COPD.S117652. eCollection 2016.
4
Exacerbations of chronic obstructive pulmonary disease.慢性阻塞性肺疾病的急性加重
Respir Care. 2003 Dec;48(12):1204-13; discussion 1213-5.
5
Cough and sputum production as risk factors for poor outcomes in patients with COPD.咳嗽和咳痰是 COPD 患者不良结局的危险因素。
Respir Med. 2011 Aug;105(8):1118-28. doi: 10.1016/j.rmed.2011.02.003. Epub 2011 Feb 25.
6
[The effect of fenspiride on the number of exacerbations and the time of first exacerbation in patients with chronic bronchitis].[非那吡啶对慢性支气管炎患者急性加重次数及首次急性加重时间的影响]
Pol Merkur Lekarski. 2005 Aug;19(110):139-43.
7
Prulifloxacin versus levofloxacin in the treatment of severe COPD patients with acute exacerbations of chronic bronchitis.普卢利沙星与左氧氟沙星治疗慢性阻塞性肺疾病急性加重期合并慢性支气管炎的疗效比较。
Pulm Pharmacol Ther. 2013 Oct;26(5):609-16. doi: 10.1016/j.pupt.2013.03.014. Epub 2013 Mar 26.
8
Characterisation of exacerbations of chronic bronchitis and COPD in Europe: the GIANT study.欧洲慢性支气管炎和 COPD 加重的特征:GIANT 研究。
Ther Adv Respir Dis. 2009 Dec;3(6):267-77. doi: 10.1177/1753465809352791. Epub 2009 Oct 30.
9
[The importance of the at risk COPD patients (Stage 0) and clinical differences].[高危慢性阻塞性肺疾病患者(0期)的重要性及临床差异]
Tuberk Toraks. 2008;56(4):382-9.
10
The therapeutic efficacy of erdosteine in the treatment of chronic obstructive bronchitis: a meta-analysis of individual patient data.厄多司坦治疗慢性阻塞性支气管炎的疗效:一项个体患者数据的荟萃分析。
Pulm Pharmacol Ther. 2010 Apr;23(2):135-44. doi: 10.1016/j.pupt.2009.10.002. Epub 2009 Oct 23.

引用本文的文献

1
Current cough and sputum assessed by the cough and sputum assessment-questionnaire (CASA-Q) is associated with quality of life impairment in cystic fibrosis.目前,通过咳嗽和咳痰评估问卷(CASA-Q)评估的咳嗽和咳痰与囊性纤维化患者的生活质量受损有关。
BMC Pulm Med. 2023 Nov 21;23(1):457. doi: 10.1186/s12890-023-02701-3.
2
Sputum-Rheology-Based Strategy for Guiding Azithromycin Prescription in COPD Patients with Frequent Exacerbations: A Randomized, Controlled Study ("COPD CARhE").基于痰液流变学的策略指导慢性阻塞性肺疾病频繁加重患者使用阿奇霉素处方:一项随机对照研究(“COPD CARhE”)
Biomedicines. 2023 Mar 1;11(3):740. doi: 10.3390/biomedicines11030740.
3
Performance of the Cough and Sputum Assessment Questionnaire (CASA-Q) in COPD: Evidence from Clinical and Online Patient Interaction Studies.
慢性阻塞性肺疾病患者咳嗽和痰液评估问卷(CASA-Q)的表现:来自临床和在线患者互动研究的证据。
Int J Chron Obstruct Pulmon Dis. 2022 Dec 10;17:3087-3096. doi: 10.2147/COPD.S381131. eCollection 2022.
4
Palliative Care Early in the Care Continuum among Patients with Serious Respiratory Illness: An Official ATS/AAHPM/HPNA/SWHPN Policy Statement.严重呼吸系统疾病患者的照护延续链中的舒缓医疗:美国胸科学会/美国临终关怀与姑息医学学会/美国护士麻醉师协会/世界卫生组织姑息治疗联盟政策声明。
Am J Respir Crit Care Med. 2022 Sep 15;206(6):e44-e69. doi: 10.1164/rccm.202207-1262ST.
5
Developing a conceptual model of symptoms and impacts in progressive fibrosing interstitial lung disease to evaluate patient-reported outcome measures.构建进行性纤维化间质性肺疾病症状与影响的概念模型,以评估患者报告的结局指标。
ERJ Open Res. 2022 May 3;8(2). doi: 10.1183/23120541.00681-2021. eCollection 2022 Apr.
6
Methods of Sputum and Mucus Assessment for Muco-Obstructive Lung Diseases in 2022: Time to "Unplug" from Our Daily Routine!2022 年黏液阻塞性肺病的痰和黏液评估方法:是时候“摆脱”我们的日常习惯了!
Cells. 2022 Feb 25;11(5):812. doi: 10.3390/cells11050812.
7
Minimal Clinically Important Differences for Patient-Reported Outcome Measures of Cough and Sputum in Patients with COPD.慢性阻塞性肺疾病患者咳嗽和痰液患者报告结局测量的最小临床重要差异。
Int J Chron Obstruct Pulmon Dis. 2020 Jan 29;15:201-212. doi: 10.2147/COPD.S219480. eCollection 2020.
8
Health-related quality of life and symptoms in patients with IPF treated with nintedanib: analyses of patient-reported outcomes from the INPULSIS® trials.特发性肺纤维化患者尼达尼布治疗的健康相关生活质量和症状:来自 INPULSIS®试验的患者报告结局分析。
Respir Res. 2020 Jan 30;21(1):36. doi: 10.1186/s12931-020-1298-1.
9
Types and applications of cough-related questionnaires.咳嗽相关问卷的类型及应用
J Thorac Dis. 2019 Oct;11(10):4379-4388. doi: 10.21037/jtd.2019.09.62.
10
Management of airway mucus hypersecretion in chronic airway inflammatory disease: Chinese expert consensus (English edition).慢性气道炎症性疾病气道黏液高分泌的管理:中国专家共识(英文版)
Int J Chron Obstruct Pulmon Dis. 2018 Jan 30;13:399-407. doi: 10.2147/COPD.S144312. eCollection 2018.